RMS Semiparametric Ordinal Longitudinal Model

I think you reanalyzed ACTT-1 in Rhode et al, ACTT-2 is Baricitinib (JAK-Inhibitor). But patient populations does seem quite similar, I don’t have access to ACTT-1 unfortunately. I shall have a look at time to recovery in ACTT-2 and how it depends on the baseline state.